Compare DoorDash Inc (DASH) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DoorDash Inc vs Quest Diagnostics Inc — how do they compare? DoorDash Inc trades at $192.17 (market cap $82.86B), while Quest Diagnostics Inc trades at $230.72 (market cap $25.06B). The key difference: DoorDash Inc is far larger — about 3.3× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays a 1.52% dividend while DoorDash Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold DoorDash Inc for 59 Days and Quest Diagnostics Inc for 56 Days on average.
| DASH | DGX | |
|---|---|---|
Market Cap | $82.86B | $25.06B |
Volume | 2,006,669 | 927,361 |
Sector | Media | Health |
52-Week High | $275.44 | $247.45 |
52-Week Low | $146.60 | $173.49 |
Typical Hold Time | 59 Days | 56 Days |
Enterprise Value | $80.82B | $30.82B |
Dividend Yield | — | 1.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DoorDash (DASH) trades at $191.24, down 1.23% on the day, with strong analyst support showing 75% buy ratings and a $255.80 consensus price target. The company demonstrates robust revenue growth from $6.6B in 2022 to $13.7B in 2025, achieving profitability with net income of $935M. Recent innovations include AI-powered text ordering and drone delivery expansion, while technical indicators show the stock trading near key support at $190 with overall bullish momentum.
DoorDash presents a compelling growth story with expanding margins and strategic initiatives, though elevated valuation multiples (P/E 100.13) and recent earnings misses warrant caution. The stock offers 34% upside to analyst targets but faces regulatory scrutiny and competitive pressures in the food delivery space. Positive cash flow trends and institutional support provide fundamental strength despite near-term volatility risks.
Quest Diagnostics (DGX) trades at $230.81, up 1.03% with consistent earnings beats in recent quarters. The stock shows bearish technical signals despite strong fundamentals including 9.19% net margins and 14.35% ROE. Recent developments include a partnership with Apple Health app and concerns about Medicare reimbursement cuts affecting future revenue streams.
The outlook remains cautiously optimistic with a $250 consensus price target representing 8.3% upside potential. Key opportunities include growth in advanced diagnostics and consumer testing demand, while risks center on Medicare payment reductions and competitive pressures in the diagnostic services market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DoorDash Inc
Founded in 2013 and headquartered in San Francisco, DoorDash is an online food order demand aggregator. Consumers can use its app to order food on-demand for pickup or delivery from merchants mainly in the U.S. The firm provides a marketplace for the merchants to create a presence online, market their offerings, and meet demand by making the offerings available for pickup or delivery. The firm provides similar service to businesses in addition to restaurants, such as grocery, retail, pet supplies, and flowers. At the end of 2020, DoorDash had over 450,000 merchants, 20 million consumers, and over 1 million dashers on its platform. In 2020, the firm generated $24.7 billion in gross order volume (up 207% year over year) and $2.9 billion in revenue (up 226%).
Read more on DASH →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
